Development Of Novel Non-PEG Stabilizer Lipids For Nucleic Acid Lipid Nanoparticles

By H. Yazdani, K. Paulson, L. Yee, S. Abbina, H. Son, N. Aibani, and A. Thomas

Polyethylene glycol (PEG)–lipids have long been a standard component in lipid nanoparticle (LNP) formulations, valued for their ability to improve colloidal stability, limit aggregation, and extend circulation after systemic delivery. But as LNP-based therapeutics advance, PEG is drawing increasing scrutiny for its potential to trigger anti-PEG antibodies and hypersensitivity reactions, particularly with repeat dosing. A new class of non-PEG stabilizer lipids offers a compelling alternative. Designed to preserve or exceed the performance of conventional PEG-lipids, these materials also open the door to greater chemical flexibility for formulation optimization. Early proof-of-concept results show that LNPs built with non-PEG stabilizers maintain critical quality attributes while delivering notably stronger in vivo and ex vivo efficacy.

For teams developing next-generation LNP therapies, this shift could broaden both formulation design and clinical potential.